By Colin Kellaher

 

Biogen Inc. (BIIB) on Tuesday said a Phase 2 study of its BIIB059 antibody in patients with the autoimmune disease lupus met its primary endpoints, showing statistically significant reduction of disease activity compared to placebo.

The Cambridge, Mass., biopharmaceutical company said the two-part study evaluated BIIB059 in individuals with active cutaneous lupus erythematosus, including chronic and subacute subtypes, with or without systemic manifestations, and in individuals with systemic lupus erythematosus with active joint and skin manifestations.

Biogen said the safety and tolerability profile of BIIB059 supports its continued development, adding that the study results support the company's goal of building a multi-franchise portfolio.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 

(END) Dow Jones Newswires

December 03, 2019 08:00 ET (13:00 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Biogen (NASDAQ:BIIB)
Historical Stock Chart
From Jul 2020 to Aug 2020 Click Here for more Biogen Charts.
Biogen (NASDAQ:BIIB)
Historical Stock Chart
From Aug 2019 to Aug 2020 Click Here for more Biogen Charts.